Compare EQH & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQH | KTTA |
|---|---|---|
| Founded | 1859 | 2020 |
| Country | United States | United States |
| Employees | 8000 | 4 |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 18.9M |
| IPO Year | N/A | N/A |
| Metric | EQH | KTTA |
|---|---|---|
| Price | $38.56 | $0.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $60.80 | $3.00 |
| AVG Volume (30 Days) | ★ 2.7M | 100.6K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $43.69 | N/A |
| Revenue Next Year | $7.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.58 | $0.28 |
| 52 Week High | $56.61 | $2.34 |
| Indicator | EQH | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 45.01 |
| Support Level | $37.05 | $0.67 |
| Resistance Level | $39.38 | $0.88 |
| Average True Range (ATR) | 1.28 | 0.05 |
| MACD | 0.26 | -0.00 |
| Stochastic Oscillator | 54.65 | 29.69 |
Equitable Holdings Inc is a financial services company providing retirement, asset management, and wealth management solutions for individual and institutional clients, operating through three segments. The Retirement segment generates the majority of revenue and offers annuities, retirement savings plans, institutional savings products, and includes the spread lending business. The Asset Management segment provides diversified investment management and related services globally through Institutional, Retail, and Private Wealth channels and reflects the business of AB. The Wealth Management segment offers advisory accounts, financial planning and advice, life insurance, and annuity products. Revenues are earned predominantly from fee income, income from investments, and insurance premiums.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).